# An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions

> **NCT05839951** · — · COMPLETED · sponsor: **Bayer** · enrollment: 818 (actual)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DRUG:** Regorafenib (BAY73-4506, Stivarga®)
- **DRUG:** TAS-102 (trifluridine and tipiracil, Lonsurf®)
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05839951
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-24
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 818 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05839951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05839951, "An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05839951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*